首页> 美国卫生研究院文献>International Journal of Hypertension >Clinical Implications of the Change in Glomerular Filtration Rate with Adrenergic Blockers in Patients with Morning Hypertension:The Japan Morning Surge-1 Study
【2h】

Clinical Implications of the Change in Glomerular Filtration Rate with Adrenergic Blockers in Patients with Morning Hypertension:The Japan Morning Surge-1 Study

机译:早晨高血压患者肾上腺素能阻滞剂改变肾小球滤过率的临床意义:日本晨潮1研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. The aim of this study was to clarify the relationship between the change in estimated glomerular filtration rate (eGFR) and urinary albumin by antihypertensive treatment. Methods. We randomized 611 treated patients with morning hypertension into either an added treatment group, for whom doxazosin was added to the current medication, or a control group, who continued their current medications. We compared the change in eGFR and urinary albumin creatinine ratio (UACR) between the groups. Results. The extent of the reduction in eGFR was significantly greater in the added treatment group than in the control group (−3.83  versus −1.08 mL/min/1.73 m2, P = 0.001). In multivariable analyses, the change in eGFR was positively associated with the change in UACR in the added treatment group (β = 0.20, P = 0.001), but not in the control group (β = −0.002, P = 0.97). When the changes in eGFR were divided by each CKD stage, eGFR was significantly more decreased in stage 1 than in the other stages in the added treatment group (P < 0.001), but no differences were seen in the control group (P = 0.44). Conclusion. The reduction of eGFR could be seen only in the early stage of CKD, and this treatment appeared to have no negative effect on renal function.
机译:背景。这项研究的目的是阐明通过降压治疗估计的肾小球滤过率(eGFR)变化与尿白蛋白之间的关系。方法。我们将611例接受治疗的早晨高血压患者随机分为一个新的治疗组,在该组中将多沙唑嗪添加到当前药物中,或在一个对照组中继续使用当前药物。我们比较了两组之间eGFR和尿白蛋白肌酐比率(UACR)的变化。结果。添加的治疗组中eGFR的降低程度明显大于对照组(-3.83 vs --1.08 mL / min / 1.73 m 2 ,P = 0.001)。在多变量分析中,添加的治疗组(β= 0.20,P = 0.001)中eGFR的变化与UACR的变化呈正相关,而对照组(β= -0.002,P = 0.97)没有相关性。当按每个CKD阶段划分eGFR的变化时,添加治疗组的eGFR在第1阶段的下降明显大于其他阶段(P <0.001),但在对照组中没有发现差异(P = 0.44) 。结论。 eGFR的降低仅在CKD的早期阶段可见,这种治疗似乎对肾功能没有负面影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号